Agilent Technologies (NYSE: A) reports fiscal third-quarter 2026 results after the close on August 26, and the setup is unusually clean. The company walked out of its second quarter with revenue of $1.835 billion (up roughly 10% year over year), a 5.8% earnings beat, and non-GAAP operating margin of 26.4% — up 130 basis points. Management then raised full-year guidance. For a life-science instruments franchise that spent 2023 and 2024 fighting a brutal China downturn and a global lab-spending freeze, that combination — accelerating growth, expanding margins, and rising guidance — is exactly the inflection long-term owners wait for.
Yet the stock closes this preview at $159, within a whisker of its 52-week high of $160.27 and essentially level with the average analyst price target of about $161. So the honest question is not “is Agilent a great business?” — it plainly is — but “how much of the recovery is already in the price?” This article works through that tension in detail.
Three investment points frame the analysis. First, Agilent’s real moat is not its instruments; it is the 66% of revenue that now comes from consumables, services, and software — a razor-and-blade annuity that compounds regardless of the capital-equipment cycle, and which carries CrossLab operating margins near 32%. Second, the fiscal 2026 guidance raise (revenue of $7.39–$7.49 billion and non-GAAP EPS of $6.00–$6.10) signals that the destocking and China air-pocket that crushed sentiment in 2024 are genuinely behind the company, and the Q3 print on August 26 is the confirmation event. Third, valuation is the sticking point: at roughly 24 times forward earnings, Agilent trades like the high-quality compounder it is, which means the return from here comes from earnings growth and buybacks, not multiple re-rating.
This report covers Agilent’s business model and segment structure, the size and growth of the analytical-instruments industry, a detailed moat analysis, five years of financial history using company filings, a scenario-based valuation built off consensus forward EPS, the key risks, and a concrete rating with an entry-and-exit plan. The goal is to tell you not just whether Agilent is a good company, but whether $159 is a good price.
1. Company Overview
Agilent Technologies is one of the anchor franchises of the analytical laboratory. Spun out of Hewlett-Packard in 1999, it builds the instruments that scientists use to measure, separate, and identify the molecular composition of physical samples — liquid chromatography (LC), mass spectrometry (LC/MS and GC/MS), gas chromatography (GC), spectroscopy, and genomics tools — and then sells the columns, reagents, vials, and software those instruments consume every single day, plus the service contracts that keep them running.
Crucially, Agilent’s revenue is not mostly about selling boxes. In the most recent quarter, instruments were only 34% of revenue, while consumables, services, and informatics made up 66%. That is the single most important fact about the company: the majority of its business is recurring, sticky, and largely decoupled from whether a given lab is buying new capital equipment this quarter.
Revenue by segment (fiscal Q2 2026):
Segment Revenue YoY growth Operating margin What it is Agilent CrossLab Group (ACG) $759M +6% ~32.0% Services, consumables, informatics, lab management — the annuity engine Life Sciences & Diagnostics Markets Group (LDG) $732M +12% ~22.0% Pharma/biopharma tools, genomics, pathology, cell analysis Applied Markets Group (AMG) $344M +14% ~23.3% Chemicals, energy, food, environmental, semiconductor labs Total $1,835M ~+10% ~26.4% (non-GAAP total)
The segment structure itself is worth noting: Agilent reorganized into this markets-focused operating model (CrossLab / Life Sciences & Diagnostics / Applied Markets) at the start of fiscal 2025, replacing an older group structure. The reorganization put the recurring CrossLab annuity at the center of the company’s reporting and incentives — a signal of where management believes the durable value sits.
End markets. Agilent’s largest customer vertical is pharmaceutical and biopharmaceutical (roughly a third of revenue), where its LC and LC/MS platforms are workhorses in drug discovery, QA/QC, and manufacturing. Beyond pharma it serves clinical diagnostics and genomics, chemicals and advanced materials, food safety, environmental testing, and the semiconductor and electronics labs that need trace-level analysis. This diversification matters: when pharma capex froze in 2023–2024, the chemicals, food, and environmental verticals cushioned the blow, and the services book kept compounding throughout.
Market position. Agilent sits in the top tier of a consolidated, oligopolistic industry alongside Thermo Fisher Scientific, Danaher, Waters, and Bruker. In its core chromatography and mass-spec niches it is a share leader or co-leader, and its installed base of instruments — hundreds of thousands of units sitting in regulated labs worldwide — is the foundation that feeds the consumables and service annuity for a decade or more per instrument.
Ownership and governance. Agilent is a widely held S&P 500 component with institutional ownership above 85% — index funds, and the large active managers that favor high-return-on-capital compounders. Insider ownership is modest, typical for a company of this size and age. The capital-allocation record is shareholder-friendly: the diluted share count has fallen from roughly 300 million in fiscal 2022 to about 282 million today, and the company pays a small but steadily growing dividend.
2. Industry Analysis
2-1. Market Size and Growth Trajectory
Agilent operates inside the global analytical and life-science instruments market — the tools, consumables, and services that laboratories use to analyze matter. Depending on how the boundaries are drawn (instruments alone, or instruments plus the much larger consumables-and-services tail), industry estimates place the total addressable market in the range of roughly $65–$75 billion today, growing at a mid-single-digit compound annual rate. The instruments-plus-consumables-plus-informatics TAM that Agilent specifically addresses is often framed by the company and its peers at around $70 billion.
The growth rate is unspectacular but remarkably durable: this is a mid-single-digit CAGR industry with a very long runway and low cyclicality at the consumables layer. The reason is structural. Analytical testing is embedded in the regulatory and quality infrastructure of the modern economy. Every approved drug, every liter of municipal water, every batch of packaged food, every semiconductor process node, and every environmental compliance filing generates mandatory, repeated laboratory measurement. That demand does not disappear in a recession; at worst, the capital-equipment portion of it gets deferred while the consumables and services portion keeps flowing.
Where is the industry in its cycle? After a genuine boom in 2021–2022 (post-pandemic lab build-out, biopharma funding surge, and China stimulus), the sector fell into a sharp down-cycle in 2023 and 2024: biopharma cut capital budgets, distributors worked down bloated inventories, and Chinese demand collapsed under both macro weakness and an anti-corruption campaign that froze hospital and academic procurement. Agilent’s own revenue fell from $6.85 billion in fiscal 2022 to $6.51 billion in fiscal 2024 as a direct result. The industry is now in the early-to-mid innings of a recovery — order books are normalizing, China is stabilizing off a low base, and Agilent’s return to ~10% reported growth in the most recent quarter is the clearest evidence that the trough is behind it.
2-2. Structural Growth Drivers
Driver 1 — The shift from instruments to recurring revenue. The most important structural trend in this industry is the deliberate migration of revenue mix toward consumables, services, software, and informatics. Every instrument Agilent places is a multi-year annuity: an LC or mass-spec system consumes columns, vials, reagents, and calibration standards continuously, and regulated labs sign multi-year service contracts to guarantee uptime and compliance. As the global installed base grows, the recurring tail grows with it — and it grows at higher, more stable margins than the hardware. Agilent’s 66% recurring mix and CrossLab’s ~32% operating margin are the financial expression of this driver. Over a decade this trend mechanically raises industry margins and lowers cyclicality, and Agilent is one of its purest beneficiaries. This is not a one-quarter phenomenon; it is a multi-year, self-reinforcing mix shift that compounds independent of the macro.
Driver 2 — Biopharma complexity and the rise of large molecules. Drug pipelines are shifting from small-molecule chemistry toward biologics, cell and gene therapies, mRNA, GLP-1 peptides, and other large, structurally complex molecules. These modalities are far harder to characterize, purify, and quality-control than a simple pill, and they require more — and more sophisticated — analytical instrumentation per program: high-resolution mass spectrometry, advanced LC, cell-analysis platforms, and genomics tools. As the world’s biopharma R&D and manufacturing base scales, the analytical intensity per dollar of drug output rises. Agilent’s genomics, cell-analysis, and LC/MS franchises are directly levered to this multi-decade shift, which underpins the above-market growth in the Life Sciences & Diagnostics segment (+12% in the latest quarter).
Driver 3 — Regulation, food safety, environmental testing, and “forever chemicals.” Analytical testing is fundamentally a compliance market, and the compliance burden only ratchets upward. Tightening food-safety standards, expanding environmental monitoring (PFAS “forever chemicals” testing is a fast-growing new category requiring trace-level LC/MS), semiconductor purity requirements at advanced nodes, and stricter pharmaceutical quality regimes all expand the volume of mandated measurement. Each new regulation effectively legislates demand for the exact instruments and consumables Agilent sells. Unlike discretionary capital spending, regulatory-driven testing is non-negotiable and grows structurally with the complexity of the products and materials modern economies produce. This is the slow, boring, powerful tailwind beneath the whole industry.
Short-term versus long-term: in the near term (the next few quarters), the swing factor is cyclical — the pace of China’s recovery and biopharma capital-equipment orders, which is precisely what the August 26 print will illuminate. Over the long term, the three structural drivers above deliver a reliable mid-single-digit top line that Agilent converts into high-single/low-double-digit EPS growth through mix, margin, and buybacks.
2-3. Competitive Landscape
The analytical-instruments industry is a consolidated oligopoly, which is a large part of its appeal. A handful of scaled players compete on installed base, breadth, and service reach rather than on price, and switching costs keep the customer rosters remarkably stable.
Company (ticker) Approx. annual revenue Positioning / moat Relative margin profile Thermo Fisher (TMO) ~$43B (est.) The scale giant — broadest catalog, dominant distribution High, scale-driven Danaher (DHR) ~$24B (est.) Bioprocessing + diagnostics leader post-Veralto spin High, DBS-driven Agilent (A) ~$7.2B (TTM) LC/MS + chromatography leadership, 66% recurring Gross ~53%, oper ~23% Waters (WAT) ~$3B (est.) LC/MS pure-play, very high recurring mix Very high (~30% oper, est.) Bruker (BRKR) ~$3.4B (est.) Scientific instruments, research-heavy Lower, more cyclical Mettler-Toledo (MTD) ~$3.9B (est.) Precision lab/industrial instruments Very high (~30%, est.)
(Peer revenue and margin figures are approximate consensus estimates for context; only Agilent’s figures are drawn directly from its filings and the live data pull.)
Why is Agilent well positioned within this group? Three reasons. First, focus with scale: it is large enough (over $7 billion in revenue) to fund heavy R&D — roughly $455 million in fiscal 2025 — and maintain a global service network, yet focused enough on chromatography and mass spectrometry to lead those specific categories rather than being a mile-wide, inch-deep catalog. Second, recurring-revenue quality: at 66% recurring, Agilent’s mix rivals the best pure-plays and far exceeds the more hardware-heavy or research-grant-dependent competitors, giving it lower earnings volatility through the cycle. Third, the razor-and-blade lock-in: its enormous installed base is a captive consumables and service annuity that competitors cannot easily attack, because displacing an installed, method-validated Agilent instrument in a regulated lab is expensive and risky for the customer. Note also the ongoing reshaping of the competitive set — Waters’ proposed combination with a large diagnostics-and-bioscience business would create a bigger direct rival in LC/MS-adjacent markets — but industry consolidation historically preserves, rather than erodes, the pricing discipline that makes this such a high-return industry.
3. Economic Moat Analysis
Agilent’s competitive advantage is wide, durable, and — importantly — measurable in the financials. It rests on two reinforcing pillars.
Moat Type 1: Switching Costs (the razor-and-blade installed base)
The primary moat is switching costs, and they are formidable. When a pharmaceutical company, a clinical lab, or a food-testing facility installs an Agilent LC/MS system, it does far more than buy hardware. It validates analytical methods on that specific instrument, trains its scientists on Agilent’s software and workflows, builds those methods into regulatory filings (FDA, EMA), and embeds the instrument into audited, compliant standard operating procedures. Ripping that out to save a few percent on a competitor’s box means re-validating methods, re-training staff, re-filing with regulators, and risking a compliance gap — a cost that dwarfs any hardware savings.
The evidence is in the revenue structure. 66% of Agilent’s revenue is recurring — the consumables, service contracts, and software that the installed base pulls through year after year. An installed instrument typically has a useful life of 7–10 years, and over that life the cumulative spend on columns, reagents, service, and software often exceeds the original purchase price. This is the textbook razor-and-blade model, but with an additional regulatory lock that ordinary consumer razor-and-blade businesses lack. The result is pricing power: Agilent can raise consumables and service prices modestly every year with minimal volume loss, which shows up as the steady gross margin near 53% and CrossLab operating margins around 32%.
Moat Type 2: Intangible Assets (brand, R&D, and regulatory trust)
The second pillar is intangible: two-plus decades of brand equity, a deep patent and know-how base, and — most importantly — regulatory trust. In a lab where an incorrect measurement can mean a failed drug batch, a mis-diagnosis, or a compliance violation, the reliability and accepted-standard status of the instrument is paramount. Agilent’s brand is a shorthand for “will pass the audit,” and that trust is nearly impossible for a new entrant to replicate. Sustaining it requires the ~$455 million of annual R&D Agilent spends to keep its platforms at the technological frontier (high-resolution mass spec, cell analysis, informatics), which in turn protects the installed base that feeds the consumables annuity. R&D, brand, installed base, and recurring revenue form a self-reinforcing flywheel.
Moat Durability Assessment
Will this moat hold for 5–10 years? On balance, yes, with clear-eyed caveats. The forces that entrench it — regulatory method validation, multi-year instrument lifecycles, and the compliance premium — are structural and if anything strengthening as biopharma modalities grow more complex. The consumables annuity is not a fad; it grows mechanically with the installed base.
The genuine risks to the moat are three. First, technological disruption: a step-change platform (for example, a fundamentally new detection or sequencing technology) could, over time, erode the value of an incumbent’s installed base — though in practice these industries adopt new technology incrementally, and incumbents with the scale to acquire or develop it (Agilent included) tend to co-opt disruption rather than be destroyed by it. Second, customer concentration in pharma: a prolonged biopharma funding winter would slow instrument placements and, eventually, the annuity growth rate. Third, China and geopolitics: a structurally larger, more protectionist Chinese domestic-instrument industry could chip at share in that market over a decade. None of these threatens the moat in the near term, and Agilent’s R&D budget and balance sheet give it the means to defend it. The moat is wide and durable; the debate is about price, not quality.
4. Financial Analysis
Agilent’s five-year financial record (fiscal years end October 31) tells the story of a high-quality compounder that took a cyclical hit and is now recovering, all figures drawn from company filings.
Fiscal year Revenue Gross profit Operating income (GAAP) Net income Diluted EPS Diluted shares FY2022 $6,848M $3,722M $1,618M $1,254M $4.18 300M FY2023 $6,833M $3,465M $1,350M $1,240M $4.19 296M FY2024 $6,510M $3,535M $1,488M $1,289M $4.43 291M FY2025 $6,948M $3,643M $1,479M $1,303M $4.57 285M TTM (latest) ~$7,230M — — ~$1,410M $4.98 282M
The story behind each year. FY2022 was the cyclical peak ($6.85B revenue, 23.6% GAAP operating margin) on post-pandemic and China-stimulus demand. FY2023 revenue held flat but operating income fell to $1,350M — a ~19.8% margin — dragged down by a $277 million asset-impairment charge and the first signs of the demand slowdown. FY2024 was the trough on the top line: revenue fell to $6.51 billion as biopharma capex froze, distributors destocked, and China procurement collapsed; yet Agilent defended profitability well, with operating margin recovering to ~22.9% and EPS actually rising to $4.43 on aggressive cost control and buybacks. FY2025 marked the return to growth: revenue reached $6.95 billion (a record), and diluted EPS rose to $4.57. The TTM figures — revenue of roughly $7.23 billion and net income of about $1.41 billion — show the recovery accelerating, with the momentum that carried the ~10% growth of the most recent quarter.
Margins and returns. Agilent is a genuinely high-return business: gross margin sits around 53%, GAAP operating margin around 23% (non-GAAP operating margin reached 26.4% in the latest quarter), net margin near 19.5%, and return on equity of about 21% with return on assets around 11%. These are the metrics of a company with real pricing power and capital efficiency, not a commodity manufacturer.
Balance sheet and free cash flow. The balance sheet is solid and conservatively levered. At fiscal 2025 year-end, Agilent held about $1.79 billion in cash against $3.35 billion of total debt, for net debt of roughly $1.57 billion — a debt-to-equity ratio of just 0.47 and net leverage around 1x EBITDA. This is an investment-grade balance sheet with ample flexibility.
Cash generation is the highlight. Agilent produced free cash flow of about $1.15 billion in fiscal 2025, $1.37 billion in FY2024, and $1.47 billion in FY2023 — consistently converting roughly 90% or more of net income into free cash. Management returns that cash aggressively and sensibly: in FY2025 it spent $425 million on buybacks and $282 million on dividends (a dividend of roughly $1.00 per share, a yield near 0.6%), and it has retired nearly 6% of the share count over three years. This is textbook compounder capital allocation — high-margin recurring revenue converting to abundant free cash, most of which is returned to owners while the balance sheet stays pristine. Agilent does not have a “path to profitability” question; it has a margin-expansion and cash-return story, and both are intact.
5. Valuation
Agilent is profitable and richly cash-generative, so an earnings-based approach is the right lens. The live data pull provides the anchors: a current price of $159, trailing EPS of $4.98 (a trailing P/E of about 31.9x), and consensus forward EPS (next fiscal year) of $6.61, which puts the stock at a forward P/E of about 24.1x (159 ÷ 6.61 = 24.06). The gap between the trailing ~32x and forward ~24x reflects both strong expected earnings growth and the difference between GAAP trailing figures and the non-GAAP consensus the Street uses for forward estimates — either way, the forward multiple is the relevant one for a valuation, and it is the basis I use below.
Method: forward P/E on consensus EPS. For a high-quality, mid-single-digit-growth compounder in a consolidated industry, a mid-20s forward multiple is the historical norm — Agilent has typically traded in a ~22–28x forward range, and its highest-quality peers (Waters, Mettler-Toledo) command similar or richer multiples. Applying a range of exit multiples to the $6.61 forward EPS:
– Bear case — 20x × $6.61 = ~$132. Multiple compresses toward the low end of its historical band on a stalled China recovery or a fresh biopharma capex air-pocket. Roughly 17% downside from $159.
– Base case — 25x × $6.61 = ~$165. Agilent trades at a fair, in-line-with-history multiple as the recovery continues at a measured pace. Roughly 4% upside from $159.
– Bull case — 28.5x × $6.61 = ~$188. Margin expansion and re-accelerating growth earn a premium multiple as investors pay up for the quality and recurring-revenue durability. Roughly 18% upside from $159.
The base case lands at about $165, essentially in line with the average analyst price target of ~$161 and only modestly above today’s $159. I agree with the consensus that Agilent is fairly valued here, and I want to be explicit about what that means: at $159, the stock is not cheap. The margin of safety is thin, and the return from this price is unlikely to come from the multiple expanding. Instead, it comes from the earnings growing — high-single to low-double-digit EPS growth via revenue, margin mix, and buybacks — compounding at a fair multiple over time. That is a perfectly good reason to own a business like this; it is not a reason to expect a quick re-rating.
This is why the entry discipline in the conclusion matters. Buying a great business at a full price caps your forward return to roughly its earnings-growth rate; buying the same business on a cyclical pullback (Agilent traded near $108 within the past year) is where the outsized returns are made. The quality is not in question. The price is merely fair.
6. Risk Factors
Risk 1 — Valuation and a thin margin of safety. This is the most immediate risk and it deserves top billing. At $159 the stock sits at a ~24x forward multiple, near its 52-week high, and roughly at consensus fair value. That leaves little cushion. If the August 26 print merely meets expectations, the stock could stall or drift; if it disappoints even modestly, a high-quality name priced for continued execution can de-rate quickly toward the high-$130s or low-$140s. A buyer at today’s price is paying full freight for a business whose recovery is already partly discounted, and the risk/reward is therefore asymmetric to the downside in the near term. This is a “great company, fair-to-full price” situation, and the biggest way to lose money in such names is to overpay at the top of the cycle.
Risk 2 — China and geopolitical exposure. China is one of Agilent’s most important growth markets and was the epicenter of the 2023–2024 downturn, when macro weakness and an anti-corruption campaign froze hospital, academic, and industrial procurement. The recovery is real but fragile and could stall or reverse on renewed Chinese economic weakness or policy shocks. Layered on top is genuine geopolitical risk: US–China trade and technology tensions, potential tariffs or export controls on scientific instruments, and a Chinese industrial policy that explicitly promotes domestic-instrument champions to displace Western incumbents over time. A structurally larger, state-favored Chinese competitor set is a slow but real threat to Agilent’s share and pricing in that market.
Risk 3 — Biopharma cyclicality and end-market demand. Roughly a third of Agilent’s revenue comes from pharma and biopharma, and instrument placements are sensitive to those customers’ capital budgets and funding environment. A prolonged biotech funding winter, pressure on drug pricing that tightens pharma R&D budgets, or a broader capex retrenchment would slow the instruments business and, with a lag, decelerate the consumables and services annuity that depends on a growing installed base. While the 66% recurring mix cushions the blow relative to a pure-hardware vendor, Agilent is not immune to the demand cycle — as fiscal 2024’s revenue decline demonstrated. Foreign-exchange volatility (a large share of revenue is non-US) is a further, ongoing swing factor on both the top line and reported margins.
7. Conclusion & Exit Plan
Investment rating: Buy (with entry discipline) — a high-quality compounder at a fair, not cheap, price.
Agilent is one of the highest-quality franchises in the life-science tools industry: a wide switching-cost moat, a 66% recurring-revenue mix that compounds through the cycle, ~53% gross and ~26% non-GAAP operating margins, ~21% return on equity, abundant free cash flow, a pristine balance sheet, and a management team that returns cash sensibly while shrinking the share count. The August 26 earnings report should confirm that the 2023–2024 downturn is genuinely behind the company. For long-term owners, this is a business worth holding for a decade.
The one reservation is price. At $159 — near its 52-week high and roughly at consensus fair value — the stock offers a thin margin of safety, and the return from here is likely to track earnings growth rather than come from multiple expansion. That argues not against owning Agilent, but for how you own it: build the position with discipline rather than chasing the high.
Entry price range. Begin accumulating on weakness below $150, with a preferred build-out zone of $135–$148. A starter position at the current $159 is defensible for a true long-term holder, but I would keep it small and reserve capital to add on the cyclical pullbacks this stock reliably provides (it traded near $108 within the past year).
Exit conditions:
– Target achieved: trim into strength — take roughly 25% off at the base-case target of $165, and trim a further portion toward the bull-case $185–$190 if margin expansion and growth re-accelerate.
– Fundamental break: reassess if the recurring-revenue mix stops growing, if non-GAAP operating margin falls back below ~24% for two consecutive quarters, or if China/biopharma demand deteriorates enough to push revenue back into year-over-year decline — any of which would undermine the compounding thesis.
– Time-based: reassess in 6–12 months, with the August 26 Q3 print and the subsequent fiscal 2026 close as the key checkpoints.
Item Detail Company Agilent Technologies (A) Current Price $159 Target Price (base) ~$165 Upside (base) ~4% Rating Buy (accumulate on weakness) Key Thesis 66% recurring-revenue razor-and-blade moat compounding at ~25x earnings; cyclical recovery confirmed by Aug 26 print Main Risk Full valuation near 52-week high with a thin margin of safety; China/biopharma demand
—
This article is for informational purposes only and does not constitute investment advice. All data sourced from public filings, analyst reports, and news as of the publication date. Invest at your own discretion.
This content is general investment information provided to an indefinite/unspecified audience by a quasi-investment advisory business registered under Korea’s Financial Investment Services and Capital Markets Act, and is not personalized 1:1 investment advice tailored to any individual investor. This analysis is for informational purposes only and is not a solicitation to invest. All investment decisions and their consequences rest solely with the investor. The estimates and assumptions in this report are as of the writing date (2026-08-22) and may not materialize depending on market conditions and geopolitical variables. Financial data used reflects sources such as company filings and analyst consensus, and the scenarios and price targets represent the author’s conservative assessment. All investments carry the risk of principal loss, and past performance or analytical track record does not guarantee future results. As of the writing date, the author does not hold a position in this stock. The author’s holdings and positions may change without prior notice depending on market conditions.
함께 읽으면 좋은 글
- argenx VYVGART Franchise Expansion: Why an 18-Quarter Growth Streak and a $5B Run-Rate Justify a Buy in 2026
- Workiva Agentic AI Connected Reporting Platform: Why the GAAP Profitability Inflection and 18x Forward P/E Point to 13% Base-Case Upside (35% Bull)
- Neurocrine Biosciences Beyond Ingrezza: Why the CRENESSITY and VYKAT XR Ramp Points to 37% Upside in 2026
- Advanced Energy Industries (AEIS) Data Center Power Surge: Record Semiconductor Revenue and the Path to a $429 Price Target
- [2026년 08월 재분석] Oceaneering International (OII): Why We Keep Trimming a $51.59 Stock After the $400M–$440M EBITDA Guidance Raise and Citi’s Target Jump to $52